Lixte Biotechnology Holdings, Inc.
News
LIXTE Receives U.S. Patent Issue Notification for Immune Oncology
Globe Newswire Patent Covers Combining LIXTE's LB-100 with Various Innovative Cancer Immunotherapies PASADENA, Calif., Sept. 04, 2024 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (Nasdaq: LIXT and...\n more…
Lixte Biotechnology Holdings, Inc. (NASDAQ:LIXT) Sees Significant Increase in Short Interest
Ticker Report Lixte Biotechnology Holdings, Inc. (NASDAQ:LIXT - Get Free Report) was the recipient of a large growth in short interest in August. As of August 15th, there was short interest totalling 9,600 shares...\n more…
First Patient Dosed with LIXTE's LB-100 in New Clinical Trial to Treat Colorectal Cancer, Collaborating with NKI, Supported by Major Pharma Company
Globe Newswire PASADENA, Calif., Aug. 26, 2024 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (Nasdaq: LIXT and LIXTW) ( LIXTE or the Company ), today announced the dosing of the first patient in a new...\n more…
LIXTE Biotechnology Provides Update On Recent Activities and Developments
Globe Newswire -Collaboration with NKI and Funding Support for New Colorectal Cancer Clinical Trial by Major Pharma Company- -Distinguished Oncologist Jan Schellens Joins LIXTE as Chief Medical Officer...\n more…
LIXT Stock Earnings: Lixte Biotech Hldgs Reported Results for Q2 2024
InvestorPlace InvestorPlace - Stock Market News, Stock Advice & Trading Tips\nLixte Biotech Hldgs just reported results for the second quarter of 2024.\nThe post LIXT Stock Earnings: Lixte Biotech Hldgs Reported...\n more…